Assignee
G1 THERAPEUTICS INC
US·57 granted patents·29 pending applications·897 citations·filing 2013–2023
Top patents by PatentIndex Score
86 records- 0199US10189850B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·17 cites·1 claims
- 0299US10189849B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·18 cites·1 claims
- 0399US10189851B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·19 cites·1 claims
- 0499US9499564B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 22, 2016·34 cites·2 claims
- 0599US9481691B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 1, 2016·31 cites·2 claims
- 0699US9102682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Aug 11, 2015·42 cites·16 claims
- 0799US8829012B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 9, 2014·47 cites·47 claims
- 0899US8822683B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 2, 2014·55 cites·37 claims
- 0999US8691830B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Apr 8, 2014·53 cites·42 claims
- 1099US8598197B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·65 cites·58 claims
- 1199US8598186B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·81 cites·24 claims
- 1298US11040042B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·5 cites·2 claims
- 1398US10927120B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·3 claims
- 1498US10085992B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Oct 2, 2018·16 cites·9 claims
- 1598US10076523B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2016·Granted Sep 18, 2018·15 cites·15 claims
- 1698US9957276B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·14 cites·57 claims
- 1798US9931345B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·14 cites·20 claims
- 1898US9527857B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2014·Granted Dec 27, 2016·31 cites·74 claims
- 1998US9487530B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Nov 8, 2016·36 cites·50 claims
- 2098US9464092B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Oct 11, 2016·29 cites·54 claims
- 2197US11717523B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·3 cites·21 claims
- 2297US11654148B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2021·Granted May 23, 2023·4 cites·16 claims
- 2397US10696682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jun 30, 2020·6 cites·12 claims
- 2497US10434104B2HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·7 cites·10 claims
- 2597US9260442B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Feb 16, 2016·42 cites·14 claims
- 2696US10925878B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Feb 23, 2021·5 cites·85 claims
- 2796US10709711B2Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·6 cites·8 claims
- 2896US10660896B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·5 cites·21 claims
- 2996US9717735B2Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2015·Granted Aug 1, 2017·16 cites·60 claims
- 3095US12168666B2Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2021·Granted Dec 17, 2024·8 cites·27 claims
- 3195US11090306B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2019·Granted Aug 17, 2021·9 cites·6 claims
- 3295US10988479B1Morphic forms of trilaciclib and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2020·Granted Apr 27, 2021·15 cites·14 claims
- 3395US10981887B2Benzothiophene estrogen receptor modulatorsG1 THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·3 cites·19 claims
- 3495US10966984B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·5 cites·30 claims
- 3595US10413547B2Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·11 cites·3 claims
- 3695US9745316B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Aug 29, 2017·14 cites·20 claims
- 3794US12285431B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2021·Granted Apr 29, 2025·2 cites·9 claims
- 3894US12139494B2Morphic forms of G1T38 and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2022·Granted Nov 12, 2024·3 cites·1 claims
- 3994US11708337B2Synthesis of 1,4-diazaspiro[5.5]undecan-3-oneG1 THERAPEUTICS INC·Filed 2021·Granted Jul 25, 2023·5 cites·26 claims
- 4094US11357779B2G1T38 superior dosage regimesG1 THERAPEUTICS INC·Filed 2020·Granted Jun 14, 2022·7 cites·52 claims
- 4193US11395821B2Treatment of EGFR-driven cancer with fewer side effectsG1 THERAPEUTICS INC·Filed 2019·Granted Jul 26, 2022·9 cites·7 claims
- 4293US11261193B2Morphic forms of G1T38 and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·5 cites·20 claims
- 4392US10865210B2Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-aminesG1 THERAPEUTICS INC·Filed 2018·Granted Dec 15, 2020·9 cites·37 claims
- 4492US10376519B2Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2017·Granted Aug 13, 2019·5 cites·10 claims
- 4592US10231969B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumorsG1 THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·12 cites·13 claims
- 4692US9856268B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted Jan 2, 2018·9 cites·20 claims
- 4791US11629150B2Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-aminesG1 THERAPEUTICS INC·Filed 2020·Granted Apr 18, 2023·3 cites·5 claims
- 4891US11446295B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumorsG1 THERAPEUTICS INC·Filed 2019·Granted Sep 20, 2022·4 cites·6 claims
- 4991US10654831B2Antiproliferative pyrimidine-based compoundsG1 THERAPEUTICS INC·Filed 2018·Granted May 19, 2020·5 cites·19 claims
- 5090US10829490B2Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·5 cites·29 claims
Showing the top 50 of 86 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when G1 THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →